Perilla Extract improves gastrointestinal discomfort in a randomized placebo controlled double blind human pilot study

Table 4 Mean values and standard deviation (SD) for women of Gastrointestinal symptoms and the delta changes between the run in phase and the intake phase (week 3-4)

Women (N = 38)	Placebo				Perilla				Placebo	Perilla
Women (N = 38)	Run In	Intake week 1-2	Intake week 3-4	p value (ANOVA)	Run In	Intake week 1-2	Intake week 3-4	p value (ANOVA)	Delta week 3-4 to run in	Delta week 3-4 to run in	Comparison between groups (95% CI)
Bloating	1.54	1.65	1.4	0.1641	1.43	1.27	0.91	0.0002	-0.14	-0.51	-0.031 to 0.787
SD	0.67	0.58	0.68		0.85	0.71	0.83		0.67	0.57	-0.031 to 0.787
Passage of gas	1.54	1.69	1.49	0.2572	1.62	1.51	1.28	0.0272	-0.04	-0.34	-0.126 to 0.727
SD	0.65	0.47	0.59		0.81	0.68	0.77		0.60	0.69	-0.126 to 0.727
GI rumbling	1.6	1.47	1.3	0.1685	1.64	.1.17	0.9	0.0002	-0.30	-0.74	-0.080 to 0.948
SD	0.78	0.92	0.85		0.81	0.59	0.68		0.70	0.85	-0.080 to 0.948
Feeling of fullness	1.05	1.13	0.86	0.1016	0.96	0.76	0.51	0.0062	-0.19	-0.45	-0.173 to 0.709
SD	0.78	0.61	0.67		0.79	0.67	0.59		0.60	0.73	-0.173 to 0.709
Abdominal discomfort	1.14	1.16	0.91	0.0843	1.2	0.83	0.57	0.0004	-0.24	-0.63	-0.031 to 0.828
SD	0.87	0.84	0.84		0.89	0.64	0.65		0.48	0.79	-0.031 to 0.828

For the comparison within group p values of repeated measures ANOVA and for the comparison between groups the 95% confidence intervals of differences are shown.

ISSN: 2662-7671